Akari Therapeutics, Plc
AKTX
$0.33
-$0.01-1.82%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.53% | -12.61% | -20.43% | -5.71% | -18.10% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.79% | -33.17% | -16.34% | 5.27% | 4.26% |
| Operating Income | 28.79% | 33.17% | 16.34% | -5.27% | -4.26% |
| Income Before Tax | 16.36% | 39.07% | -8.17% | -97.75% | -116.37% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.75% | 39.07% | -8.17% | -97.75% | -116.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.75% | 39.07% | -8.17% | -97.75% | -116.37% |
| EBIT | 28.79% | 33.17% | 16.34% | -5.27% | -4.26% |
| EBITDA | 28.80% | 33.16% | 16.29% | -5.21% | -4.21% |
| EPS Basic | 79.12% | 80.00% | 56.18% | -1.50% | -33.82% |
| Normalized Basic EPS | 83.30% | 82.00% | 66.99% | 15.23% | -20.05% |
| EPS Diluted | 79.12% | 80.00% | 56.18% | -1.32% | -33.60% |
| Normalized Diluted EPS | 83.30% | 82.00% | 66.99% | 15.37% | -19.85% |
| Average Basic Shares Outstanding | 238.57% | 252.97% | 221.60% | 161.59% | 89.53% |
| Average Diluted Shares Outstanding | 243.48% | 257.14% | 226.92% | 166.29% | 89.41% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |